Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

PHASE3CompletedINTERVENTIONAL
Enrollment

545

Participants

Timeline

Start Date

February 25, 2019

Primary Completion Date

September 23, 2021

Study Completion Date

July 19, 2022

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

Secukinumab

Secukinumab 300mg every 2 or every 4 weeks

DRUG

Placebo

Placebo 300mg every 2 or every 4 weeks

Trial Locations (108)

652

Novartis Investigative Site, Saida

1011

Novartis Investigative Site, Lausanne

1015

Novartis Investigative Site, Guatemala City

1220

Novartis Investigative Site, Makati City

1431

Novartis Investigative Site, Sofia

2013

Novartis Investigative Site, Soweto

2400

Novartis Investigative Site, Copenhagen NV

4000

Novartis Investigative Site, Liège

4032

Novartis Investigative Site, Debrecen

5800

Novartis Investigative Site, Pleven

6725

Novartis Investigative Site, Szeged

7000

Novartis Investigative Site, Ho Chi Minh City

7400

Novartis Investigative Site, Kaposvár

8000

Novartis Investigative Site, Aarhus

9000

Novartis Investigative Site, Ghent

10000

Novartis Investigative Site, Zagreb

10029

Novartis Investigative Site, New York

10789

Novartis Investigative Site, Berlin

10990

Novartis Investigative Site, George Town

13353

Novartis Investigative Site, Berlin

13500

Novartis Investigative Site, Martigues

18012

Novartis Investigative Site, Granada

19055

Novartis Investigative Site, Schwerin

20246

Novartis Investigative Site, Hamburg

23507

Novartis Investigative Site, Norfolk

28006

Novartis Investigative Site, Madrid

28009

Novartis Investigative Site, Madrid

30328

Novartis Investigative Site, Sandy Springs

33134

Novartis Investigative Site, Coral Gables

33609

Novartis Investigative Site, Tampa

34098

Novartis Investigative Site, Istanbul

34662

Novartis Investigative Site, Altunizade

35010

Novartis Investigative Site, Las Palmas de Gran Canaria

35040

Novartis Investigative Site, Izmir

38039

Novartis Investigative Site, Talas / Kayseri

42055

Novartis Investigative Site, Saint-Etienne

44100

Novartis Investigative Site, Cona

46256

Novartis Investigative Site, Indianapolis

46940

Novartis Investigative Site, Manises

48149

Novartis Investigative Site, Münster

50586

Novartis Investigative Site, Kuala Lumpur

51100

Novartis Investigative Site, Reims

52621

Novartis Investigative Site, Ramat Gan

60126

Novartis Investigative Site, Ancona

63104

Novartis Investigative Site, St Louis

63110

Novartis Investigative Site, St Louis

68144

Novartis Investigative Site, Omaha

69120

Novartis Investigative Site, Heidelberg

76031

Novartis Investigative Site, Rouen

77401

Novartis Investigative Site, Bellaire

78660

Novartis Investigative Site, Pflugerville

80100

Novartis Investigative Site, Johor Bahru

80131

Novartis Investigative Site, Napoli

81377

Novartis Investigative Site, München

83800

Novartis Investigative Site, Toulon

87000

Novartis Investigative Site, Limoges

91054

Novartis Investigative Site, Erlangen

92103

Novartis Investigative Site, San Diego

92160

Novartis Investigative Site, Antony

92677

Novartis Investigative Site, Whittier

94160

Novartis Investigative Site, Saint-Mandé

97080

Novartis Investigative Site, Würzburg

97239

Novartis Investigative Site, Portland

97401

Novartis Investigative Site, Banská Bystrica

100000

Novartis Investigative Site, Hanoi

110221

Novartis Investigative Site, Bogotá

119074

Novartis Investigative Site, Singapore

169608

Novartis Investigative Site, Singapore

191123

Novartis Investigative Site, Saint Petersburg

214031

Novartis Investigative Site, Smolensk

308205

Novartis Investigative Site, Singapore

440009

Novartis Investigative Site, Nagpur

454048

Novartis Investigative Site, Chelyabinsk

6423906

Novartis Investigative Site, Tel Aviv

02111

Novartis Investigative Site, Boston

C1056ABJ

Novartis Investigative Site, CABA

S2000DBS

Novartis Investigative Site, Rosario

C1023AAB

Novartis Investigative Site, Capital Federal

L4M 7G1

Novartis Investigative Site, Barrie

L4C 9M7

Novartis Investigative Site, Richmond Hill

J2B 5L4

Novartis Investigative Site, Drummondville

J7Z 3B8

Novartis Investigative Site, Saint-Jérôme

080002

Novartis Investigative Site, Barranquilla

400 11

Novartis Investigative Site, Ústí nad Labem

586 33

Novartis Investigative Site, Jihlava

06202

Novartis Investigative Site, Nice

06847

Novartis Investigative Site, Dessau

564 03

Novartis Investigative Site, Thessaloniki

161 21

Novartis Investigative Site, Athens

01010

Novartis Investigative Site, Guatemala City

400 706

Novartis Investigative Site, Navi Mumbai

00133

Novartis Investigative Site, Roma

LT 50161

Novartis Investigative Site, Kaunas

LT 08661

Novartis Investigative Site, Vilnius

4624 VT

Novartis Investigative Site, Bergen op Zoom

90-436

Novartis Investigative Site, Lodz

35 055

Novartis Investigative Site, Rzeszów

04141

Novartis Investigative Site, Warsaw

081 81

Novartis Investigative Site, Prešov

0001

Novartis Investigative Site, Pretoria

08003

Novartis Investigative Site, Barcelona

CH-8091

Novartis Investigative Site, Zurich

DY1 2HQ

Novartis Investigative Site, Dudley

BD5 0NA

Novartis Investigative Site, Bradford

B15 2TH

Novartis Investigative Site, Birmingham

HG2 7SX

Novartis Investigative Site, Harrogate

E1 1BB

Novartis Investigative Site, London

SE1 9RT

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY